{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T11:35:02Z","timestamp":1763120102942,"version":"3.45.0"},"reference-count":23,"publisher":"Wiley","issue":"21","license":[{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"vor","delay-in-days":3,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Thoracic Cancer"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background\/Objectives<\/jats:title>\n                    <jats:p>Thoracostomy and pleurodesis are the mainstay of management for malignant pleural effusions (MPEs). However, pleurodesis may not be effective for patients with MPEs and non\u2010expandable lungs. Intrapleural chemotherapeutic agents such as hypotonic cisplatin are reportedly useful for treating MPEs with expandable lungs; however, their efficacy in patients with non\u2010expandable lungs remains unclear. We aimed to analyze the efficacy and safety of intrapleural administration of hypotonic cisplatin in patients with MPEs and non\u2010expandable lungs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analyzed patients with MPEs of thoracic malignancies who were administered intrapleural hypotonic cisplatin. We investigated the changes in drained fluid volume, radiological outcomes at 4\u2009weeks, thoracentesis\u2010free survival, and adverse events. Between June 2009 and September 2022, 62 patients with MPEs received 69 administrations of hypotonic cisplatin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The most frequent primary site was the lungs (90.3%), and the mean drained fluid volume per day decreased by 65% (95% confidence interval [CI] 58%\u201372%) after intrapleural hypotonic cisplatin administration. At 4\u2009weeks post\u2010administration, MPE volumes decreased in 33 (53.2%) patients, remained unchanged in 22 (35.4%), and increased in seven (11.3%), based on frontal plane chest radiographs. The median thoracentesis\u2010free survival was 456\u2009days (95% CI, 122\u2013842\u2009days), the 30\u2010day thoracentesis\u2010free survival rate was 86.1%, and the 90\u2010day survival rate was 70.8%. In total, 37 patients (59.7%) were censored. The most frequent adverse event was pleural empyema, observed in four patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Intrapleural hypotonic cisplatin administration decreased or stabilized pleural effusion and may be useful for suppressing MPE with non\u2010expandable lungs.<\/jats:p>\n                    <jats:p>ClinicalTrials.gov identifier: E23\u20100003.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/1759-7714.70181","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T02:55:37Z","timestamp":1762311337000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Intrapleural Administration of Hypotonic Cisplatin for Patients With Malignant Pleural Effusions and Non\u2010Expandable Lungs"],"prefix":"10.1111","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7542-7146","authenticated-orcid":false,"given":"Wataru","family":"Mori","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine Juntendo University Graduate School of Medicine  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoyasu","family":"Mimori","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine Juntendo University Graduate School of Medicine  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine Juntendo University Graduate School of Medicine  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shun","family":"Sorimachi","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine Juntendo University Graduate School of Medicine  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinya","family":"Fujioka","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine Juntendo University Graduate School of Medicine  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruki","family":"Hirakawa","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine Juntendo University Graduate School of Medicine  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2886-6638","authenticated-orcid":false,"given":"Yoshihiro","family":"Masui","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine Juntendo University Graduate School of Medicine  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taichi","family":"Miyawaki","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine Juntendo University Graduate School of Medicine  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takehito","family":"Shukuya","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine Juntendo University Graduate School of Medicine  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhisa","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine Juntendo University Graduate School of Medicine  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,11,4]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.117.1.73"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201807-1415ST"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2010.136994"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/MCP.0b013e3283615b67"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00349-2018"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.127.3.909"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/MAJ.0b013e31815f1a44"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.119.6.1641"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2019.08.1920"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1010-7940(00)00422-X"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60418-9"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5223(19)33776-6"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6603319"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2021-217959"},{"volume-title":"Common Terminology Criteria for Adverse Events (CTCAE) v5.0","year":"2017","author":"Cancer Institute Network","key":"e_1_2_12_16_1"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-022-00631-7"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00686048"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1994.45"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005340.pub4"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa052985"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.77.8613"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2008-0275"},{"key":"e_1_2_12_24_1","article-title":"Interventions for the Management of Malignant Pleural Effusions: A Network Meta\u2010Analysis","volume":"5","author":"Clive A. O.","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Thoracic Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1759-7714.70181","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T11:31:46Z","timestamp":1763119906000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1759-7714.70181"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":23,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1111\/1759-7714.70181"],"URL":"https:\/\/doi.org\/10.1111\/1759-7714.70181","archive":["Portico"],"relation":{},"ISSN":["1759-7706","1759-7714"],"issn-type":[{"type":"print","value":"1759-7706"},{"type":"electronic","value":"1759-7714"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"2025-06-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70181"}}